Skip to main content
Erschienen in:

07.06.2024 | Thoracic Oncology

The Battle for Accuracy: Identifying the Most Effective Grading System for Lung Invasive Mucinous Adenocarcinoma

verfasst von: Jia Jia, MD, Guochao Zhang, MD, LuoPei Wei, MD, Linlin Qi, MD, Xiaojun Wang, MD, Lin Li, MD, Hua Zeng, MD, Jianwei Wang, MD, Qi Xue, MD, Jianming Ying, MD, PhD, Liyan Xue, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognostic analysis of lung invasive mucinous adenocarcinoma (IMA) is deficient due to the lack of a universally recommended histological grading system, leading to unregulated treatment approaches.

Objective

We aimed to examine the clinical trajectory of IMA and assess the viability of utilizing the existing grading system for lung invasive non-mucinous adenocarcinoma in the context of IMA.

Methods

We retrospectively collected clinicopathological data from 265 IMA patients. Each case re-evaluated the tumor grade using the following three classification systems: the 4th Edition of the World Health Organization classification system, the International Association for the Study of Lung Cancer (IASLC) grading system, and a two-tier grading system. We performed a comparative analysis of these grading systems and identified the most effective grading system for IMA.

Results

The study comprised a total of 214 patients with pure IMA and 51 patients with mixed IMA. The 5-year overall survival (OS) rates for pure IMA and mixed IMA were 86.7% and 57.8%, respectively. All three grading systems proved to be effective prognostic classifiers for IMA. The value of area under the curve at 1-, 3-, and 5-year OS was highest for the IASLC grading system compared with the other grade systems and the clinical stage. The IASLC classification system was an independent prognostic predictor (= 0.009, hazard ratio 2.243, 95% confidence interval 1.219–4.127).

Conclusion

Mixed IMA is more aggressive than pure IMA, with an OS rate on par with that of high-grade pure IMA. The IASLC grading system can better indicate prognosis and is recommended for lung IMA.
Literatur
1.
Zurück zum Zitat Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th edn. Lyon: International Agency for Research on Cancer; 2015. Travis WD, Brambilla E, Burke A, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th edn. Lyon: International Agency for Research on Cancer; 2015.
2.
Zurück zum Zitat Borczuk AC, Cooper WA, Dacic S, et al. WHO Classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. 5th edn. World Health Organization; 2021. Borczuk AC, Cooper WA, Dacic S, et al. WHO Classification of tumours pathology and genetics of tumours of the lung, pleura, thymus and heart. 5th edn. World Health Organization; 2021.
3.
Zurück zum Zitat Moreira AL, Ocampo PS, Xia Y, Zhong H, Mino-Kenudson M. A grading system for invasive pulmonary adenocarcinoma: a proposal from the iaslc pathology committee. Journal of Thoracic Oncology. 2020;15(10):1599–610.CrossRefPubMedCentral Moreira AL, Ocampo PS, Xia Y, Zhong H, Mino-Kenudson M. A grading system for invasive pulmonary adenocarcinoma: a proposal from the iaslc pathology committee. Journal of Thoracic Oncology. 2020;15(10):1599–610.CrossRefPubMedCentral
4.
Zurück zum Zitat Gow CH, Hsieh MS, Liu YN, Lee YH, Shih JY. Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma. Cancers (Basel). 2021;13(16):4103.CrossRefPubMedCentral Gow CH, Hsieh MS, Liu YN, Lee YH, Shih JY. Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma. Cancers (Basel). 2021;13(16):4103.CrossRefPubMedCentral
5.
Zurück zum Zitat Chang WC, Zhang YZ, Lim E, Nicholson AG. Prognostic impact of histopathologic features in pulmonary invasive mucinous adenocarcinomas. Am J Clin Pathol. 2020;154(1):88–102.CrossRef Chang WC, Zhang YZ, Lim E, Nicholson AG. Prognostic impact of histopathologic features in pulmonary invasive mucinous adenocarcinomas. Am J Clin Pathol. 2020;154(1):88–102.CrossRef
6.
Zurück zum Zitat Matsui T, Sakakura N, Koyama S, et al. Comparison of surgical outcomes between invasive mucinous and non-mucinous lung adenocarcinoma. Ann Thorac Surg. 2021;112(4):1118–26.CrossRef Matsui T, Sakakura N, Koyama S, et al. Comparison of surgical outcomes between invasive mucinous and non-mucinous lung adenocarcinoma. Ann Thorac Surg. 2021;112(4):1118–26.CrossRef
7.
Zurück zum Zitat Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer. 2016;102:82–8.CrossRef Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS. Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer. 2016;102:82–8.CrossRef
8.
Zurück zum Zitat Geles A, Gruber-Moesenbacher U, Quehenberger F, et al. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch. 2015;467(6):675–86.CrossRef Geles A, Gruber-Moesenbacher U, Quehenberger F, et al. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch. 2015;467(6):675–86.CrossRef
9.
Zurück zum Zitat Wang Y, Liu J, Huang C, et al. Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database. BMC Cancer. 2021;21(1):148.CrossRefPubMedCentral Wang Y, Liu J, Huang C, et al. Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database. BMC Cancer. 2021;21(1):148.CrossRefPubMedCentral
10.
Zurück zum Zitat Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol. 2010;5(6):830–6.CrossRef Casali C, Rossi G, Marchioni A, et al. A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice. J Thorac Oncol. 2010;5(6):830–6.CrossRef
11.
Zurück zum Zitat Shim HS, Kenudson M, Zheng Z, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10(8):1156–62.CrossRef Shim HS, Kenudson M, Zheng Z, et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2015;10(8):1156–62.CrossRef
12.
Zurück zum Zitat Lee HY, Cha MJ, Lee KS, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas. J Thorac Oncol. 2016;11(7):1064–73.CrossRef Lee HY, Cha MJ, Lee KS, et al. Prognosis in resected invasive mucinous adenocarcinomas of the lung: related factors and comparison with resected nonmucinous adenocarcinomas. J Thorac Oncol. 2016;11(7):1064–73.CrossRef
13.
Zurück zum Zitat Xu X, Shen W, Wang D, et al. Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. Transl Lung Cancer Res. 2022;11(3):420–31.CrossRefPubMedCentral Xu X, Shen W, Wang D, et al. Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma. Transl Lung Cancer Res. 2022;11(3):420–31.CrossRefPubMedCentral
14.
Zurück zum Zitat Lee HY, Lee HY, Lee KS, Kwon OJ, Shim YM, Han J. Reliability of small biopsy or cytology for the diagnosis of pulmonary mucinous adenocarcinoma. J Clin Pathol. 2014;67(7):587–91.CrossRef Lee HY, Lee HY, Lee KS, Kwon OJ, Shim YM, Han J. Reliability of small biopsy or cytology for the diagnosis of pulmonary mucinous adenocarcinoma. J Clin Pathol. 2014;67(7):587–91.CrossRef
15.
Zurück zum Zitat Moon SW, Choi SY, Moon MH. Effect of invasive mucinous adenocarcinoma on lung cancer-specifific survival after surgical resection: a population-based study. J Thorac Dis. 2018;10:3595–608.CrossRefPubMedCentral Moon SW, Choi SY, Moon MH. Effect of invasive mucinous adenocarcinoma on lung cancer-specifific survival after surgical resection: a population-based study. J Thorac Dis. 2018;10:3595–608.CrossRefPubMedCentral
16.
Zurück zum Zitat Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey. J Thorac Oncol. 2010;5:29–33.CrossRef Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a national cancer database survey. J Thorac Oncol. 2010;5:29–33.CrossRef
17.
Zurück zum Zitat Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer. 1986;57(8):1555–64.CrossRef Clayton F. Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer. 1986;57(8):1555–64.CrossRef
18.
Zurück zum Zitat Gaikwad A, Souza CA, Inacio JR, et al. Aerogenous metastases: a potential game changer in the diagnosis and management of primary lung adenocarcinoma. AJR Am J Roentgenol. 2014;203(6):W570–82.CrossRef Gaikwad A, Souza CA, Inacio JR, et al. Aerogenous metastases: a potential game changer in the diagnosis and management of primary lung adenocarcinoma. AJR Am J Roentgenol. 2014;203(6):W570–82.CrossRef
19.
Zurück zum Zitat Takanashi Y, Tajima S, Tsukui M, et al. Non-mucinous lepidic predominant adenocarcinoma presenting with extensive aerogenous spread. Rare Tumors. 2016;8(4):6580.CrossRefPubMedCentral Takanashi Y, Tajima S, Tsukui M, et al. Non-mucinous lepidic predominant adenocarcinoma presenting with extensive aerogenous spread. Rare Tumors. 2016;8(4):6580.CrossRefPubMedCentral
20.
Zurück zum Zitat Matsubara D, Soda M, Yoshimoto T, et al. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas. Cancer Sci. 2017;108(9):1888–96.CrossRefPubMedCentral Matsubara D, Soda M, Yoshimoto T, et al. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas. Cancer Sci. 2017;108(9):1888–96.CrossRefPubMedCentral
21.
Zurück zum Zitat Hwang DH, Sholl LM, Rojas-Rudilla V, et al. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2016;11(4):496–503.CrossRef Hwang DH, Sholl LM, Rojas-Rudilla V, et al. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2016;11(4):496–503.CrossRef
22.
Zurück zum Zitat Natsume K, Ye J, Mukai Y, et al. Discrepancies between morphological and immunohistochemical classifications are associated with prognoses and subtypes of lung cancer. Anticancer Res. 2024;44(2):711–22.CrossRef Natsume K, Ye J, Mukai Y, et al. Discrepancies between morphological and immunohistochemical classifications are associated with prognoses and subtypes of lung cancer. Anticancer Res. 2024;44(2):711–22.CrossRef
23.
Zurück zum Zitat Deng C, Zheng Q, Zhang Y, et al. Validation of the novel international association for the study of lung cancer grading system for invasive pulmonary adenocarcinoma and association with common driver mutations. J Thorac Oncol. 2021;16:1684–93.CrossRef Deng C, Zheng Q, Zhang Y, et al. Validation of the novel international association for the study of lung cancer grading system for invasive pulmonary adenocarcinoma and association with common driver mutations. J Thorac Oncol. 2021;16:1684–93.CrossRef
24.
Zurück zum Zitat Rokutan-Kurata M, Yoshizawa A, Ueno K, et al. Validation study of the international association for the study of lung cancer histologic grading system of invasive lung adenocarcinoma. J Thorac Oncol. 2021;16:1753–8.CrossRef Rokutan-Kurata M, Yoshizawa A, Ueno K, et al. Validation study of the international association for the study of lung cancer histologic grading system of invasive lung adenocarcinoma. J Thorac Oncol. 2021;16:1753–8.CrossRef
25.
Zurück zum Zitat Fujikawa R, Muraoka Y, Kashima J, et al. Clinicopathologic and genotypic features of lung adenocarcinoma characterized by the international association for the study of lung cancer grading system. J Thorac Oncol. 2022;17(5):700–7.CrossRef Fujikawa R, Muraoka Y, Kashima J, et al. Clinicopathologic and genotypic features of lung adenocarcinoma characterized by the international association for the study of lung cancer grading system. J Thorac Oncol. 2022;17(5):700–7.CrossRef
26.
Zurück zum Zitat Hou L, Wang T, Chen D, Omics Classifier for Pulmonary Nodules (MISSION) Collaborative Group, et al. Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study. Mod Pathol. 2022;35(6):749–56.CrossRef Hou L, Wang T, Chen D, Omics Classifier for Pulmonary Nodules (MISSION) Collaborative Group, et al. Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study. Mod Pathol. 2022;35(6):749–56.CrossRef
Metadaten
Titel
The Battle for Accuracy: Identifying the Most Effective Grading System for Lung Invasive Mucinous Adenocarcinoma
verfasst von
Jia Jia, MD
Guochao Zhang, MD
LuoPei Wei, MD
Linlin Qi, MD
Xiaojun Wang, MD
Lin Li, MD
Hua Zeng, MD
Jianwei Wang, MD
Qi Xue, MD
Jianming Ying, MD, PhD
Liyan Xue, MD
Publikationsdatum
07.06.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15541-0

Neu im Fachgebiet Chirurgie

Nur selten ernste Komplikationen bei endoskopischer Sinuschirurgie

Etwa 3% der Menschen mit einer endoskopischen Nasennebenhöhlenoperation entwickeln ausgeprägtes Nasenbluten. Andere Komplikationen, wie Verletzungen des Nervus opticus oder eine Meningitis, treten nur äußerst selten auf, legt eine Registeranalyse nahe.

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Mechanische Herzklappe beschert jüngeren Betroffenen längeres Leben

Patienten und Patientinnen bevorzugen bioprothetische Herzklappen gegenüber mechanischen Klappenprothesen. Diese Wahl könnte sich zumindest für jüngere Patienten nachteilig auswirken: Ihnen bietet eine mechanische Klappe anscheinend einen Überlebensvorteil.

Darmpolyp weg – Peptid-Gel gegen Nachblutungen drauf?

Das Nachblutungsrisiko nach einer endoskopischen Mukosaresektion von flachen kolorektalen und duodenalen Adenomen war in der deutschen PURPLE-Studie mit einem hämostatischen Gel nicht kleiner als ohne Prophylaxe.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.